Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer

已完结 10 由逸云发布于 2025/2/28 14:30:14

DOI:10.1021/acs.oprd.4c00362
作者：Steve Avery, Jamie M. Buske, Doris Chen, Herman Chen, Xin Chen, Andrew R. Davidson, Jean-Nicolas Desrosiers, Hanqing Dong, Noalle Fellah, David F. Fernández, John Grosso, Lu Han, Teri Hochdorfer, Amb
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：A commercial process for vepdegestrant (1), the most advanced PROTAC protein degrader in human clinical trials, has been developed to support clinical and commercial needs. The process featu

应助信息

13小时前

caomin

656a6baaf59e11efa63b34735aa3bc31.pdf 已采纳

13小时前

Book学术机器人

2025/2/28 14:30:14 未找到该文献，机器人已退出，请等待人工下载

2025/2/28 14:30:14 Book学术AI机器人收到请求，开始寻找文献

2025/2/28 14:30:14 已向机器人发送请求

13小时前

逸云发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Taylor & FrancisCharacterization of the complete chloroplast genome of <i>Chasmanthium latifolium</i> (Michx.) H.O.Yates, 1966 (Poaceae).